Work

The impact of comprehensive pharmaceutical care on medication safety in gynecologic oncology chemotherapy patients

Year: 2025

Type: article

Abstract: To evaluate the impact of our hospital's full-course pharmacy service on the safety and rationality of medication in patients with gynecologic malignancies undergoing chemotherapy. A retrospective cohort analysis was conducted on patients who underwent chemotherapy in the Gynecologic Oncology Ward at Peking University First Hospital between September 2022 and September 2024. Patients were divided into a control group, who received routine pharmaceutical care based on clinical medication prescription review, and the intervention group, who received comprehensive pharmaceutical care throughout their treatment. This included prescription review, medication education, drug consultation, and adverse reaction management. The incidence of severe adverse reactions, the appropriateness of leukopoietic treatment and monitoring, and the rate of unplanned hospital admissions were compared between the two groups. The intervention group demonstrated a significantly lower incidence of severe nausea (6.1 % vs 11.4 %, P = 0.034), anorexia (3.3 % vs 9.3 %, P = 0.003), and leukopenia (9.4 % vs 15.7 %, P = 0.034) compared to the control group. Additionally, the appropriateness of leukopoietic treatment (93.5 % vs 85.0 %, P = 0.001) and monitoring (89.2 % vs 65.0 %, P < 0.001), as well as the rate of unexpected hospital admissions (2.2 % vs 6.4 %, P = 0.013), have shown significant improvement in the intervention group. Comprehensive pharmaceutical care has a positive impact on medication safety for gynecologic oncology patients, significantly reducing the incidence of severe adverse reactions and the rate of unplanned hospital admissions. • Comprehensive pharmaceutical care significantly reduces severe nausea, anorexia, and leukopenia in chemotherapy. • Pharmacist interventions boosts leukopoietic therapy appropriateness (93.5 % vs 85.0 %). • Lowers unplanned hospital admission rates (2.2 % vs 6.4 %) in gynecologic oncology patients.

Source: Exploratory Research in Clinical and Social Pharmacy

DOI: 10.1016/j.rcsop.2025.100681